老年非瓣膜房颤患者华法林抗凝治疗的可行性及抗凝强度探讨  

Feasibility of Warfarin Anticoagulation Treatment for Elderly Patients with Nonvalvular Atrial Fibrillation and Study on Anticoagulation Intensity

作　　者：后梅[1] 

机构地区：[1]昆明医科大学第一附属医院干疗科,云南昆明650000

出　　处：《中外医疗》2016年第5期131-132,共2页China & Foreign Medical Treatment

摘　　要：目的分析在治疗老年非瓣膜房颤患者的过程中应用华法林抗凝治疗的可行性,并且对华法林的抗凝强度进行分析。方法随机从2012年1月—2014年6月来该院治疗非瓣膜房颤的患者中选出110例,将其随机分为两个小组,对其中一组患者采用阿司匹林的方法进行治疗,作为对比组,共50例患者;对另外一组患者则采用华法林的方法进行治疗,作为研究组,共60例患者。同时,将研究组中30例患者的凝血酶原时间国际标准化比值控制1.3-1.6之间,记作研究Ⅰ组;将另30例患者的控制在2.6-3.0之间,记作研究Ⅱ组。结果经过对各组患者相关数据的分析可以看出,研究组患者的终点事件发生率(3.66%)明显对于对比组(32.00%),并且研究Ⅰ组的终点事件发生几率(3.33%)要低于研究Ⅱ组(13.33%),各组数据差异具有统计学意义(P<0.05)。结论在治疗老年非瓣膜房颤的过程中,利用华法林抗凝疗法能够有效降低终点事件的发生几率。Objective To analyze the feasibility of the application of warfarin anticoagulation treatment for elderly patients with nonvalvular atrial fibrillation and anticoagulation intensity. Methods 110 cases of patients with nonvalvular atrial fibrillation treated in our hospital from January 2012 to June 2014 were randomly selected and randomly divided into two groups,the control group（n=50） were treated with aspirin, the research group（n=60）were treated with warfarin, at the same time, the prothrombin time of international normalised ratios（INR）of 30 cases in the research group controlled between 1.3 and 1.6,and the 30 cases were regarded as the researchⅠgroup, the INR of the other 30 cases in the research group controlled between 2.6 and 3.0, the 30 cases were regarded as the research Ⅱ group. Results the related data analysis of each group showed that the incidence of endpoint events in the research group was obviously lower than that in the control group（3.66% vs 32.00%）, the incidence of endpoint events in the research Ⅰgroup was lower than that in the research Ⅱ group,（3.33% vs 13.33%）, there was a big difference between each data, and the difference was statistically significant（P0.05）.Conclusion Warfarin anticoagulant treatment for elderly patients with nonvalvular atrial fibrillation can effectively reduce the incidence of endpoint events.

关 键 词：老年非瓣膜房颤 华法林 阿司匹林 可行性 抗凝强度 

分 类 号：R972[医药卫生—药品]